{
  "ticker": "LLY",
  "target_date": "2025-03-10",
  "actual_date": "2025-03-10",
  "collected_at": "2025-12-08T11:29:51.696246",
  "price": {
    "open": 849.05,
    "high": 858.28,
    "low": 821.08,
    "close": 825.0362548828125,
    "volume": 5962900,
    "change_1d_pct": -4.58,
    "change_7d_pct": -8.33,
    "change_30d_pct": 5.83
  },
  "technicals": {
    "rsi_14": 44.02,
    "sma_20": 879.7,
    "sma_50": 822.45,
    "macd": 16.373,
    "macd_signal": 24.328,
    "macd_histogram": -7.955,
    "bb_upper": 937.04,
    "bb_lower": 822.35,
    "price_vs_sma20_pct": -6.21,
    "price_vs_sma50_pct": 0.31,
    "volume_ratio": 1.69
  },
  "fundamentals": {
    "market_cap": 891190116352,
    "pe_ratio": 48.70774,
    "forward_pe": 43.87136,
    "price_to_book": 37.429405,
    "price_to_sales": 14.998201,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.6,
    "pct_from_52w_low": 59.37
  },
  "macro": {
    "spy": {
      "price": 555.71,
      "change_1d_pct": -2.66,
      "change_7d_pct": -5.65
    },
    "vix": {
      "level": 27.86,
      "signal": "HIGH_FEAR"
    },
    "treasury_10y": {
      "yield_pct": 4.21
    },
    "dollar_index": {
      "level": 103.91
    },
    "gold": {
      "price": 2891.0
    },
    "regime": "BEAR_HIGH_VOL"
  },
  "news": [
    {
      "headline": "Amgen: Riding The MariTide Of Monthly Weight Loss",
      "source": "SeekingAlpha",
      "datetime": 1741625200,
      "summary": "Amgen stock rose 13% as obesity drug MariTide advances. Click here to find out why AMGN stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=3ec2b5102da8b330ae6a137f5e4d951e50cb5c459820cacda196d8a84ae9be96"
    },
    {
      "headline": "Novo Nordisk: CagriSema Disappoints Again",
      "source": "SeekingAlpha",
      "datetime": 1741611136,
      "summary": "Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, and stay competitive. Click for more.",
      "url": "https://finnhub.io/api/news?id=0a93f2015f1580d5dfe39a873aa02c717da2e058d2167fb48ae6257e0bbdc20c"
    },
    {
      "headline": "Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study",
      "source": "Finnhub",
      "datetime": 1741610360,
      "summary": "INDIANAPOLIS - Late-breaking results from Eli Lilly and Company and Incyte found adolescent patients with severe alopecia areata treated with once-daily, oral baricitinib 4 mg and 2 mg saw...",
      "url": "https://finnhub.io/api/news?id=e6daed9e467c15a08293b7e8ca356e870bfd1ad21d4e8f5115ec2436c9ad1d37"
    },
    {
      "headline": "Lilly's EBGLYSS single monthly maintenance injection achieved completely clear skin at three years in half of patients with moderate-to-severe atopic dermatitis",
      "source": "Finnhub",
      "datetime": 1741610242,
      "summary": "INDIANAPOLIS - New results show Eli Lilly and Company's EBGLYSS achieved deep and sustained response for patients with moderate-to-severe atopic dermatitis at three years.These findings from the...",
      "url": "https://finnhub.io/api/news?id=5a6e8ad2c07fff6da8f1aeac8700a28704415635b2dfa472ed8a0d0aab137936"
    },
    {
      "headline": "Eli Lilly and Company (LLY) Management presents at Leerink 2025 Global Healthcare Conference (Transcript)",
      "source": "SeekingAlpha",
      "datetime": 1741607262,
      "summary": "Eli Lilly and Company (NYSE:LLY) Leerink 2025 Global Healthcare Conference March 10, 2025 9:20 AM ETCompany ParticipantsLucas Montarce - CFOMike Czapar -...",
      "url": "https://finnhub.io/api/news?id=57ecc209f8fb43719554e558ca22bcade96957702f91606ca775f69af57c4e02"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-03-04",
      "description": "xslF345X05/form4-03042025_040301.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000141588925006450/xslF345X05/form4-03042025_040301.xml"
    },
    {
      "form": "4",
      "date": "2025-03-03",
      "description": "xslF345X05/wk-form4_1741038785.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000083/xslF345X05/wk-form4_1741038785.xml"
    },
    {
      "form": "4",
      "date": "2025-03-03",
      "description": "xslF345X05/wk-form4_1741038712.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000081/xslF345X05/wk-form4_1741038712.xml"
    },
    {
      "form": "4",
      "date": "2025-02-26",
      "description": "xslF345X05/form4-02262025_040201.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000141588925005670/xslF345X05/form4-02262025_040201.xml"
    },
    {
      "form": "4",
      "date": "2025-02-25",
      "description": "xslF345X05/form4-02252025_040201.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000141588925005456/xslF345X05/form4-02252025_040201.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}